Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2011) 26 P148

ECE2011 Poster Presentations Male reproduction (19 abstracts)

Testosterone changes over time in men with human immunodeficiency virus infection: preliminary results

G Brigante 1 , D Santi 1 , L Zirilli 1 , C Diazzi 1 , G Orlando 2 , V Gnarini 1 , C Carani 1 , G Guaraldi 2 & V Rochira 1


1Unit of Endocrinology and Metabolism, Department of Medicine, Endocrinology and Metabolism and Geriatrics, University of Modena and Reggio Emilia, Modena, Italy; 2Metabolic Clinic, Infectious and Tropical Disease Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, Italy.


Introduction: Male hypogonadism is very frequent in men treated with highly active anti-retroviral therapy (HAART) for Human Immunodeficiency Virus-1 (HIV-1) infection, reaching a prevalence of about 20%. Literature data regarding the time course of serum total testosterone (T) levels in these patients are lacking.

Aim of the study: To evaluate changes of T levels over time in HIV-positive men with an initial finding of low T (<300 ng/dl).

Methods: Measurement of T and serum LH in 111 hypogonadic HIV positive outpatients aged 31–68 years (mean 46.3 years) at baseline and after 12 months.

Results: Mean T value at baseline was 235.8 ng/dl. After 12 months, 36 subjects (32.4%) had no change in T (a variation of <50 ng/ml), 3 patients (2.7%) had a decrease (more than 50 ng/ml) and 72 patients (64.9%) had an increase in T (more than 50 ng/ml). 63 patients (56.7%) normalized T (>300 ng/ml). Mean T value at baseline of the 63 patients who restored T was 236.3±66.9 ng/ml, while mean T value at baseline of the 9 patients who didn’t normalize was 151.4±86.5 ng/ml.

Conclusions: Most of the HIV patients under HAART with an initial finding of low T present normalized T in the following months. Baseline T values seem to be predictive of the future evolution of the disease, higher T level being associated with subsequent T normalization. In HIV patients a single finding of hypotestosteronemia needs further confirmation before starting androgen therapy and often a wait-and-see approach is mandatory.

Article tools

My recent searches

No recent searches.